The cerebrospinal fluid (CSF) and serum of six patients with histologically verified intracranial germ-cell tumors were assayed serially for the presence of alphafetoprotein (AFP) and the beta subunit of human chorionic gonadotropin (HCG). Two patients had embryonal carcinomas, two had choriocarcinomas, and two had dysgerminomas. The marker profile for a given tumor in either CSF or serum correlated with the histological diagnosis; that is, embryonal carcinoma produced AFP and HCG, choriocarcinoma produced HCG, and dysgerminoma produced no markers. The marker levels in serum and CSF declined with therapy and rose usually prior to the development of overt clinical symptoms if the patient's tumor recurred. A CSFto-serum gradient of the marker levels was present in three of four patients, and the serum levels were often nol:mal when the CSF values were elevated. Ventricular marker levels were lower than the lumbar levels in two of two patients. The assay of these biological markers is a sensitive indicator of the success of therapy, and the presence of a CSF-to-serum gradient suggests that the major portion of the neoplasm rests within the central nervous system. A histological diagnosis can be inferred without the necessity of surgery in appropriate clinical contexts.
N
EOPLASMS of germ-cell origin usually arise in midline structures in children. Sites of origin include the sacrococcygeal region, mediastinum, the gonads, and the suprasellar and posterior third ventricular regions of the central nervous system (CNS). Specific types of germ-cell tumors manufacture biological markers such as alphafetoprotein (AFP) and/or human chorionic gonadotropin (HCG). One approach to classifying this group of tumors is based on the type of marker the tumor produces: choriocarcinoma produces HCG; endodermal sinus tumor, AFP; embryonal carcinoma, AFP and HCG; and dysgerminoma and teratoma, no marker? These markers can be measured in serum by means of a highly sensitive radioimmunoassay, and quantitative assessments of serial serum marker levels correlate with response to therapy? '9 We have measured these markers in cerebrospinal fluid (CSF) and serum in six patients harboring intracranial germ-cell tumors to determine whether such analysis may confirm a histological diagnosis when tissue is available, or suggest a tissue diagnosis if surgery is not performed. Serial assays have been carried out in serum and CSF to assess whether such analysis may indicate response to initial therapy, and also early recurrence of an intracranial tumor.
Case Reports
Six patients with primary intracranial germ-cell tumors verified histologically by surgical biopsy were included in this study (Table 1) . One patient had a pure embryonal carcinoma (Case 1), one patient had a mixed embryonal carcinoma and endodermal sinus tumor (Case 2), two patients had a choriocarcinoma (Cases 3 and 4), two had dysgerminomas (Cases 5 and 6). The case reports of patients with detectable markers (Cases 1 to 4) are presented below.
Case 1
This 19-year-old man presented with a 2-week history of intermittent diplopia, headache, nausea, and vomiting. On physical examination, he was confused and somnolent and had Parinaud's syndrome with failure of upward gaze, absent pupillary response to light, and convergence nystagmus. A computerized tomography (CT) scan revealed hydrocephalus with a partially calcified contrast-enhancing mass in the posterior third ventricle. A 50% gross total removal of a tumor was achieved through a posterior craniotomy incision, and the histological diagnosis was embryonal carcinoma. The CSF cytology was positive for malignant cells and the patient subsequently received neuraxis radiation therapy: 3500 rads to the whole brain and spinal axis, and a boost of 1550 rads to the tumor bed over 43 elapsed days.
His initial AFP and HCG levels were elevated in CSF and the HCG level was elevated in serum ( Table  2) . After the completion of radiation therapy, malignant cells could no longer be detected in CSF. The marker levels fell to within the normal range in CSF and serum, and the subsequent CT scans showed continued resolution of the tumor mass. Ten months after treatment, the patient remains asymptomatic and free of any signs of tumor.
Case 2
This 13-year-old boy presented with a 4-week history of increasing lethargy, headaches, and ataxia.
On physical examination, the patient was somnolent and had dysarthric speech. He had papilledema, Parinaud's syndrome, bilateral sixth nerve palsies, a mild left central facial nerve weakness, left hemiparesis, and diffuse pathological reflexes.
The CT scan revealed marked hydrocephalus with a contrast-enhancing mass filling the posterior third ventricle and extending into the right lateral ventricle. A ventriculoperitoneal shunt was placed and a biopsy was subsequently performed through a right posterior transventricular approach. The histological diagnosis was a mixed germ-cell tumor consisting of endodermal sinus and embryonal carcinoma. Postoperatively, neuraxis radiation therapy was administered. He received 3500 rads to the entire neuraxis and a 1500-rad boost to the primary tumor in 34 fractions over 46 elapsed days. Initially the patient had elevations of AFP in his ventricular CSF and serum. Subsequently, lumbar CSF was also studied and contained a marked elevation of AFP. All these levels declined with radiation therapy. Four months after the completion of radiation therapy the child developed a local tumor recurrence, and he died 4 months later after receiving various chemotherapeutic agents.
Case 3
This 8-year-old boy has been followed for congenital adrenal hyperplasia. He presented with a 2-month history of double vision, headache, somnolence, polydypsia, and rapid growth of his penis and body hair. A C T scan revealed contrast-enhancing lesions in both lateral ventricles, the corpus callosum, and the hypothalamus. An operative biopsy revealed a choriocarcinoma.
The initial CSF study was negative for malignant cells, but contained an abnormally high amount of HCG. Serum HCG determinations were normal. The patient was initially treated with high-dose intravenous methotrexate chemotherapy, with citrovorum-factor rescue; he received 14 courses of high-dose methotrexate (12.5 gm/sq m) and vincristine (1.5 mg/sq m). Later, BCNU (1,3-bis(2-chloroethyl)-l-nitrosourea), 90 mg/sq m was added to the treatment regimen. Two months after the chemotherapy was begun, the child received 2400 rads of whole-brain irradiation, with a boost of 600 rads to the local tumor, over 11 elapsed days. The patient improved clinically and remains asymptomatic 2 years after the discontinuation of chemotherapy. His CSF HCG level dropped from 50 units to a normal level after his first two high-dose methotrexate chemotherapy and citrovorum-factor treatments before treatment with BCNU or radiation therapy.
Case 4
This 12-year-old boy presented with a history of double vision, increasing lethargy, and ataxia over 3 weeks. On physical examination, the patient had bilateral sixth nerve palsies and Parinaud's syndrome. There was no papilledema. The CT scan showed a contrast-enhancing material lining both lateral Ventricles and the presence of a small, contrast-enhancing mass in the posterior third ventricle (Fig. 1) . The lumbar CSF was positive for malignant cells and there was an elevation of HCG in the CSF, but not in the serum.
A biopsy was performed through a right frontal transcortical approach. The tumor mass bled profusely even though the biopsy was small; the bleeding could not be adequately controlled, and post- operatively the patient developed an intraventricular hemorrhage. He died 13 days later. The histological diagnosis was mixed germ-cell tumor containing choriocarcinoma.
Radioimmunoassay Studies

Radioimmunoassay Techniques
Human Chorionic Gonadotropin. The beta subunit of HCG was quantitatively assessed using a modification of the highly sensitive and specific doubleantibody radioimmunoassay procedure of Vaitukaitis, et al.~~ The antiserum against the purified beta subunit of HCG was prepared in rabbits. The normal range in serum is up to 2 ng/ml. The normal range of HCG in CSF is probably less than 10% of the serum value. 7
Alphafetoprotein. The AFP is assayed by a commercially prepared double-antibody radioimmunoassay technique.* A specific antiserum to purified AFP from pooled human fetal serum is prepared in rabbits. Serum values up to 40 ng/ml are considered normal. The normal CSF range of AFP is not known.
Results
A number of conclusions were drawn from analysis of the AFP and HCG marker data in serum and CSF. The CSF marker profile correlated with the histological diagnosis ( with the histological diagnosis obtained from neurosurgical specimens. Both AFP and HCG were detected in the two patients with embryonal carcinoma, and only HCG was observed in the two patients with choriocarcinoma. No markers were detectable in the CSF or serum obtained from the two patients with dysgerminoma who were observed for over 2 years.
Serum levels of the markers were normal when the CSF levels were elevated in three of four patients (Table 3 ). The assay of CSF rather than serum was found essential to confirm the correct histological diagnosis. In Cases 1 and 4, HCG in the lumbar CSF was elevated when the serum values were negative. In Case 1, AFP in lumbar CSF was elevated when the serum was negative.
In all four patients with positive markers the levels declined with therapy, and this response was documented by reduction in tumor bulk on CT scans (Table 3 , and Figs. 2 and 3) . In Case 1 with embryonal carcinoma, the serum AFP levels were negative at all times before and after radiation therapy, while the AFP level in lumbar CSF, elevated before therapy, gradually declined over 3 months. In this patient, HCG in lumbar CSF was much higher than in serum and ventricular CSF, but fell to normal levels after radiation therapy (Fig. 2) . The patient has remained in clinical remission 10 months after the completion of his radiation therapy. His CT scan presently shows no evidence of tumor, and the levels of serum and CSF markers remain negative.
There was a CSF-to-serum gradient in the levels of the markers in three of four patients, most apparent in the lumbar CSF analysis (Table 3) . In Case 1, both AFP and HCG levels in lumbar CSF were higher than contemporaneous serum levels obtained before therapy. In Cases 3 and 4 with choriocarcinoma, the lumbar CSF levels were significantly higher than the serum levels.
The ventricular CSF levels were lower than the lumbar CSF levels in two patients with shunts, and the ventricular levels were frequently not detectable when the lumbar levels were still abnormally high. In Case 1, HCG in the ventricular CSF was either not detectable or significantly lower than the lumbar levels at all times (Table 3) . Case 2 showed a similar trend. The lumbar CSF marker levels, therefore, were higher, in spite of the fact that ventricular CSF was in closer proximity to the intracranial tumors. Myelograms at the time of diagnosis excluded any spinal metastatic lesions in these two patients.
The levels of the markers have remained negative in patients in remission and rose in CSF and serum in one patient (Case 2) with recurrence of his embryonal carcinoma. The marker levels rapidly declined after initial therapy with either radiation or chemotherapy in all four patients, and have remained negative in three of the four patients in clinical remission with negative CT scans (Table 3) .
In Case 2, the tumor recurred after radiation therapy and the clinical symptoms and marker levels rose in the CSF before the CT scan revealed an increased contrast-enhancement of the tumor. This patient, with an embryonal carcinoma, had a very high AFP level in his serum and ventricular CSF at the time of diagnosis. All levels of AFP fell during radiation therapy and AFP became undetectable in the ventricular CSF (Fig. 3) . The patient remained in clinical remission until 4 months after radiation therapy, at which time the clinical signs and symptoms recurred. The AFP levels were found elevated in lumbar and ventricular CSF and serum, and a lumbar-ventricular gradient and lumbar-serum gradient existed, but the CT scan failed to indicate tumor enlargement. Within 1 month, the patient's condition deteriorated, and the CT scan subsequently became positive.
The patient was treated with chemotherapy, initially high-dose cyclophosphamide, and, thereafter, high-dose intravenous methotrexate with citrovorumfactor rescue. A brief clinical response was observed , 1, 0001- after each course of chemotherapy, and the marker levels also fell for a brief period of time (Fig. 3) , but the patient eventually lost ground and subsequently died. The serum AFP levels rose disproportionately to ventricular CSF levels, and a bone scan and skeletal survey indicated a possible metastatic lesion in the left tibia. Therefore, the quantitative analysis of marker levels may be a very sensitive indicator of tumor viability and early recurrence.
Discussion
The value of following HCG levels simultaneously in plasma and CSF in patients with systemic germ-cell tumors has been well documented? The mean plasma:lumbar CSF HCG ratio in 73 patients with gestational choriocarcinoma without CNS involvement was 286:1.1 In 29 of 33 patients with brain metastases the plasma:CSF ratio was less than 60:1. 1 The determination of levels of AFP and HCG in CSF and serum in patients with suspected or proven intracranial germ-cell tumors is also an important aid to their diagnosis and management. In our study, there was an excellent correlation between the histological diagnosis obtained from surgical specimens and the anticipated presence of tumor markers in CSF. The simultaneous determination of marker levels in lumbar and, if possible, ventricular CSF, in addition to serum was essential. The CSF levels were higher than the serum levels at the time of diagnosis in all of the four patients whose tumors produced markers, consistent with an intracranial origin of the primary neoplasm. The serum levels were normal when the CSF levels were elevated in three of the four patients, so serum-marker analysis alone is not sufficient to exclude an intracranial germ-cell tumor. An inordinate rise in serum levels may indicate systemic metastases, as suggested by Case 2.
The lumbar CSF marker levels were higher than ventricular CSF levels in two out of two patients when assayed simultaneously, in spite of the fact that the ventricular CSF was in closer proximity to the intracranial tumors. Myelograms at the time of diagnosis excluded any spinal metastatic lesions, but the CSF cytology was positive for malignant cells. Malignant cells were present in CSF at the time of diagnosis in three of four patients, and these cells ma3 also contribute to relative marker elevation in lumbar CSF as they concentrate in this area by gravity. The higher lumbar CSF values in these patients more probably is related tO the increased protein concentration in lumbar CSF. Lumbar CSF, therefore, must be examined for markers whenever possible.
The serial determination of serum and CSF markers was a useful adjunct in determining response to treatment. The levels rapidly declined after initial therapy with either radiation or chemotherapy in four patients, and have remained negative in three of the four patients in clinical remission with negative CT scans. In one patient (Case 2) whose tumor recurred after radiation therapy, the clinical symptoms and marker levels rose in the CSF before the CT scan indicated an increased contrast-enhancement of the tumor. Therefore, the quantitative assay of marker levels may be a very sensitive indicator of tumor viability and early recurrence.
Human chorionic gonadotropin has been previously detected in the CSF and serum in one patient with an ectopic pinealoma at diagnosis) and AFP has been detected in CSF and serum at the time of relapse in another patient with an endodermal sinus tumor originating in the pineal region. '1 In the latter patient, the AFP levels were higher in the CSF than in serum on two separate occasions. Both AFP and HCG were elevated in serum in another patient with a suprasellar mixed germ-cell tumor and these levels declined after radiation therapy) Surgical approaches to posterior third ventricular neoplasms may be hazardous, and surgical morbidity and mortality are relatively high for this group of tumors. 8 Moreover, germ-cell tumors, especially choriocarcinoma, may be highly vascular and prone to spontaneous hemorrhage. Surgical manipulation may provoke uncontrollable bleeding, and may contribute to the patient's death, as in Case 4. In some cases, radiation therapy has been initiated without a histological diagnosis. 2 In appropriate clini al contexts, the finding of elevated AFP or HCG in the CSF may be sufficient for diagnosis, and radiation or chemotherapy may be instituted before surgical intervention.
